The Menopause Transition Protocol
A non-hormonal, layered protocol for the menopause transition, built in the order the evidence supports rather than the order the supplement aisle suggests. Layer 0 is bone and sleep foundation (D3 + K2 + magnesium) and is the only mandatory part. Layer 1 is a single vasomotor agent — isoflavones or black cohosh, never both. Layer 2 is optional oestrogen-metabolism support. Includes the explicit statement that hormone therapy outperforms all of it, and the criteria for when to stop layering supplements and go and get it.
Daily Schedule
Timing and dosage for each step
Layer 0 — morning, with the largest fatty meal
100 mcg
2000–4000 IU (50–100 mcg). This layer is not optional and not symptomatic — it is the bone insurance. SWAN data show bone loss starts one year BEFORE the final menstrual period, so this begins in perimenopause, not after. Dose to a 25(OH)D of 30–50 ng/mL and retest, rather than to a fixed pill count.
Layer 0 — same fatty meal, alongside D3
180 mcg
180 mcg MK-7. Routes the calcium D3 helps you absorb into the bone matrix via osteocalcin and away from arterial walls via matrix Gla protein. ⚠️ Do NOT take with warfarin without prescriber management.
Layer 0 — evening with food
2000 mg
~2 g threonate (≈144 mg elemental). Required cofactor for vitamin D activation, and evening dosing addresses the sleep fragmentation that is often the most disabling symptom of the transition. Any well-absorbed form works for the cofactor role.
Layer 1 — daily with food (choose ONE vasomotor agent)
60 mg
40–100 mg total isoflavones. The better-evidenced of the two options: ~25% hot-flash reduction after placebo subtraction, about 57% of estradiol's ceiling. Critically, give it 48 weeks — half-maximal effect arrives at 13.4 weeks. Judging it at 12 weeks is the single most common way people conclude it 'does not work'.
Layer 1 — ALTERNATIVE to the isoflavone step, never in addition
40 mg
Isopropanolic extract (iCR) only — the extract that was actually trialled. Weaker evidence than isoflavones: Cochrane found 0.07 flushes/day versus placebo. In HALT, the multibotanical-plus-soy arm was significantly WORSE than placebo at 12 months, which is why this is an either/or. Check liver enzymes at baseline and 3 months.
Layer 2 — optional, with a fat-containing meal
150 mg
Absorption-enhanced form. Shifts oestrogen metabolism toward the 2-OH pathway — proven in a 12-month RCT, but with no clinical outcome behind the biomarker. ⚠️ CONTRAINDICATED on tamoxifen: the same trial found significantly reduced endoxifen. Exposure plateaus above 200 mg.
Layer 2 — optional, split across meals
1500 mg
Inhibits gut beta-glucuronidase so conjugated oestrogen is excreted rather than reabsorbed. Grade D — the supporting literature is rodent chemoprevention work, with no human efficacy trial. Cheap, safe, and honestly labelled as mechanism-grade. Skip it without regret.
Read This Before the Protocol
Hormone therapy is the most effective treatment for vasomotor symptoms, and the 2023 nonhormone therapy position statement of The North American Menopause Society says so explicitly, recommending it be considered for menopausal women within ten years of their final menstrual period.
The same statement does not recommend supplements or herbal remedies for vasomotor symptoms. It does not recommend soy foods, soy extracts, or the soy metabolite equol. What it recommends at Level I evidence is cognitive-behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin, and fezolinetant.
This protocol exists downstream of all of that. It is for the woman who has a contraindication to hormone therapy, or has declined it, or has worked through the recommended non-hormonal options — and who wants the best available supplement layer with honest labels on every tier.
Anyone presenting a supplement stack as equivalent to hormone therapy is selling something. This one is not.
The Layer Logic
The order is deliberate, and it inverts how these products are usually marketed. The layer with the strongest evidence is the one nobody feels, and the layers people buy first have the weakest support.
| Layer | Purpose | Evidence grade | Optional? |
|---|---|---|---|
| 0 — Foundation | Bone, arterial calcium routing, sleep | B | No |
| 1 — Vasomotor | Hot flushes, night sweats | C | Yes — and pick one agent |
| 2 — Metabolism | Oestrogen clearance and excretion | C / D | Yes, freely skippable |
The protocol as a whole is graded C, to its weakest load-bearing claim rather than its strongest component. Layer 0 on its own is a solid B and is covered in more depth in the bone and arterial longevity protocol.
Layer 0 — The Part That Is Not Negotiable
The timing argument here is the single most useful fact in this whole protocol.
In the SWAN multiethnic cohort, bone mineral density loss began one year before the final menstrual period and decelerated — but did not stop — two years after it. Cumulative ten-year lumbar spine loss was 10.6%, and 7.38% of it happened inside that three-year transmenopausal window. Femoral neck loss was 9.1% cumulative, 5.8% during transmenopause.
Roughly 70% of a decade's spinal bone loss occurs in three years, and those three years begin while periods are still happening. A woman who waits until "after menopause" to think about bone has already missed most of it.
D3 drives calcium absorption, K2 routes the absorbed calcium into bone and away from arteries, magnesium is the cofactor that activates vitamin D — and, dosed in the evening, addresses the sleep fragmentation that many women rate as worse than the flushes.
Layer 1 — One Agent, Given Enough Time
Choose isoflavones or black cohosh. Not both.
That is not fussiness. In the HALT trial, the arm receiving a multibotanical plus dietary soy counselling reported vasomotor symptom intensity significantly worse than placebo at 12 months (P = 0.016). Layering botanicals in this space has an empirical downside, not just a theoretical one.
If choosing isoflavones — the better-supported option — the number that matters is duration, not dose. Model-based meta-analysis put half-maximal effect at 13.4 weeks and 80% of maximum at roughly 48 weeks, against 3.09 weeks for estradiol. Twelve-week self-experiments are how people wrongly conclude isoflavones are inert.
Two personalisation notes. Only about a third of Western women convert daidzein to S-equol, and among non-producers dietary daidzein shows no association with symptom frequency at all. If twelve months of isoflavones does nothing, non-producer status is the likeliest explanation — and direct S-equol at 10–30 mg/day is the workaround, with its best evidence in mood and general climacteric scores rather than flush counts.
If choosing black cohosh, use the isopropanolic extract at 40 mg/day, check liver enzymes at baseline and three months, and hold expectations low: Cochrane's pooled estimate across 16 trials and 2,027 women was a difference of 0.07 hot flushes per day versus placebo.
Layer 2 — Mechanism Without Outcomes
DIM and calcium-D-glucarate address different stages of the same pipeline: DIM changes which oestrogen metabolite gets made, calcium-D-glucarate helps ensure the conjugated product actually leaves the body instead of being deconjugated by gut bacteria and reabsorbed.
The full argument, including what these compounds have and have not demonstrated, is in Estrogen Metabolism: DIM and Calcium-D-Glucarate Explained. The short version: DIM has randomised human evidence that it moves the biomarker and no evidence that moving it changes an outcome — breast density did not budge in a 12-month trial. Calcium-D-glucarate has no human efficacy trial at all.
The absolute rule for this layer: DIM is contraindicated on tamoxifen. The 12-month randomised trial found significantly reduced plasma endoxifen and other tamoxifen metabolites in the DIM arm.
When to Stop Layering and Go Get Hormone Therapy
Set these thresholds before you start, so the decision is not made by sunk cost.
- Symptoms are disrupting sleep or work and twelve months of Layer 1 has not changed that
- Vasomotor symptoms started in early perimenopause — median total duration in that group exceeds 11.8 years, which is a long time to spend on a 25% intervention
- Bone density is already low on DXA, or there is a fragility fracture history
- Genitourinary symptoms — vaginal dryness, pain, urinary symptoms. No supplement in this protocol treats these; local vaginal oestrogen does, at negligible systemic exposure
- Any abnormal bleeding. This needs a diagnosis, not a supplement
Monitoring
| Marker | When | Why |
|---|---|---|
| 25(OH)D | Baseline, 8–12 weeks | Dose Layer 0 to a level, not a pill count |
| ALT / AST | Baseline, 3 months | Only if using black cohosh |
| DXA | Baseline in perimenopause | The window closes before periods do |
| Symptom diary | Weekly, 12 months | Layer 1 is slow; memory is not a measuring instrument |
| Lipids, ApoB | Baseline, annually | Cardiovascular risk shifts across the transition |
Safety and Scope
This protocol contains no hormones and no prescription agents. It is not a substitute for evaluation of abnormal bleeding, breast changes, or new pelvic symptoms. The hormonal route — pregnenolone, DHEA and maca under bloodwork supervision — is a different protocol with different risks, set out in Female Hormonal Optimization, and the two are alternatives rather than layers.
Women with hormone-sensitive cancer, on tamoxifen or aromatase inhibitors, or with liver disease should treat every layer above as a conversation with their oncologist rather than a purchase decision.